PharmaTalkRadio cover art

All Episodes

PharmaTalkRadio — 544 episodes

#
Title
1

Bridging Access Gaps: Sponsor-Led Enablement of Research-Naïve Sites to Expand Patient Reach

2

Building Trust-Driven Partnerships: AstraZeneca’s Concierge Approach to Accelerating Site Activation and Enrollment

3

Eli Lilly on Site Enablement: Co-Designing Solutions with Sites

4

What a Strategic Partnership Looks Like in Practice: Inside the Takeda–Basil Collaboration That Delivered Tenfold Enrollment

5

Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain

6

Ensuring Sustainability Throughout Drug and Device Development

7

Utilizing AI to Facilitate Combination Product Development

8

Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success

9

Advances and Opportunities in Dual Chamber Injectables

10

How Evinova is Integrating AI into Clinical Development to Bring Big Impact to Big Pharma

11

How Bayer Reorganized Their Clinical Operations Structure for Efficiency and Cost Savings

12

How Amicus Embedded Patient Advocacy into its Corporate DNA

13

Designing Clinical Trials Balancing Simplicity with Complexity

14

Platform Approaches to Streamline Combination Product Development

15

What is the State of Clinical Trial Patient Matching Right Now?

16

Balancing Innovation and Practicality in Immuno-Oncology Dose Selection

17

Leveraging Local HCPs to Decentralize Clinical Research in North Carolina

18

Using Patient Engagement and Digital Innovation to Elevate Patient Insights and Outcomes

19

What to Expect at the 2026 Patients as Partners in Clinical Research Conference

20

The Role of the CMO in BD and M&A Partnering with Pharma

21

Advances in Payload Delivery and Drug Conjugation

22

Building Up a CMO Team as Your Company Evolves

23

Beyond LNPs: Delivering Genetic Medicines with Novel Vehicles

24

Pfizer on Advancing Data Analysis Capabilities through A New EDC/CDMS Platform

25

Insights from Tufts CSDD into Evolving Trial Partnerships Models

26

ADCs, Chemotherapy, and Checkpoint Blockade in Urothelial Carcinoma

27

Understanding the Immunological Effects of Radiopharmaceuticals

28

How J&J Is Integrating Patient Centricity Across the Enterprise

29

Biogen's Nicole Murphy on Drug Delivery Innovation and the Acquisition of Alcyone Therapeutics

30

What to Expect at the 2026 IO360° Summit

31

CMOs Working Flexibly with Consultants and Fractional Expertise

32

Principles and Strategies for Designing Best-in-Class Immuno-Oncology ADCs

33

How Patient Organizations are Bridging Patient Inclusivity Gaps at the Site-Level

34

How Roche Reduced Unnecessary Protocol Amendments to Impact Timeline and Cost

35

How to Embed Clinical Research in Rural and Frontier Health Systems

36

Optimizing the Value Proposition in Small Companies with Limited Budgets

37

From the DPHARM 2024 Archives: Biogen Pilot on Using Vocal Biomarkers to Identify Potential Participants for Clinical Trials

38

Merck on Enhancing Trial Participation, Relevance, and Impact through Patient and Community Engagement

39

Ensuring Continuity in Patient Insights to Strengthen Medicine Development

40

Accelerating Patient Enrollment in Clinical Trials by Deploying a Product Model Approach

41

Stanford's Dr Crystal Mackall on the Evolution of and Future Directions in Cell Therapy

42

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

43

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

44

Directors' Talk DPHARM 2025 - AI Sessions; Part III

45

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

46

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

47

Catalyzing Change: The Business Imperative of Patient-Centric Drug Development

48

How Emerging Biopharma CMOs Can Better Partner with Patient Organizations

49

Joint Site and Sponsor Perspectives on Innovative Solutions Addressing Sites Challenges

50

What to Expect at the CRAACO: Clinical Research as a Care Option 2025 Event

51

Directors' Talk PODD 2025 - Keynotes & Key Themes

52

Enhanced Strategic FDA Collaboration: Working with CDER and CBER

53

Biomaterial Implants to Reduce Patient Burden and Improve Adherence

54

Are Site Networks the Solution to the Industry Productivity and Recruitment Challenge?

55

2025 Biotech Markets & Immuno-Oncology Outlook

56

Directors' Talk DPHARM 2025 - Pharma from the Trenches; Part II

57

Directors' Talk DPHARM 2025 - Keynotes & Key Topics; Part I

58

Streamlining Effective Patient Engagement through Pharma-Patient Advocacy Collaboration

59

Lessons Learned in the Development and Introduction of Closed Loop Systems

60

Best Practices and Potential Pitfalls Enriching Clinical Trials with PROs

61

Operationalizing the Patient Voice for Long-Term Protocol Planning and Execution

62

Navigating Data Quality and Scalability Challenges when Using Real-World Data from EHRs

63

Addressing the Realities of Scaling T-Cell Therapies for Patient Access and Affordability

64

The Current Status of Patient Centricity in Medicine Development

65

Patients as Partners Caregiver Keynote - The Life-Changing Power of a Clinical Trial

66

Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape

67

Sustained Release Innovations to Reduce Patient Burden

68

How Pharma Is Adopting Generative AI Across Clinical Development

69

Tufts Center for Study of Drug Development on Evolving Clinical Trial Partnerships

70

New Approaches to Achieve Targeted Brain Delivery Without Increasing Toxicity

71

Partnering with Patients in Clinical Development Using the Biopsychosocial Model

72

Vaccine Delivery Innovations

73

How PALADIN Consortium Aims to Enhance Efficient Patient Advocacy-Industry Collaborations

74

What CMOs Need to Know and Do When Preparing for Product Launch

75

What to Expect at the 2025 Patients as Partners EU Conference

76

Understanding Financial Barriers to Getting More Coverage for Patients in Clinical Trials

77

How Montefiore Gets Early Stage Clinical Trials to Under-Resourced Communities

78

Investment Trends in Immuno-Oncology

79

Advances in Pulmonary Delivery of Biologics

80

Strategies for CMOs to Scale Up Effectively as Their Biotech Company Evolves

81

Boehringer Ingelheim on Collaborations in Clinical Development for Launch Readiness

82

Payer Perspectives on Drug Delivery

83

Patient Engagement: Practical Approaches for Emerging Biotech CMOs

84

Immuno-Oncology Debate 2024 on Solving Cancer’s Top Challenges

85

CMO Misunderstandings about Clinical Operations and How to Improve

86

How Roche is Maximizing the Impact of Patient Insights in Early Development

87

Designing and Developing Drug Delivery for Lower and Middle-Income Countries

88

Making Clinical Research a Feasible Care Option Using Modern Software Infrastructure

89

Using Patient Insights Meaningfully throughout the Medicine & Disease Lifecycle

90

Innovative Approach for Elevating Patient-Centric Solutions in Pediatric Trials

91

Incorporating Quantitative Values of Patient Perspectives into Trial Design

92

Accessing a Novel Source of Patient Experience Data to Improve Clinical Research

93

Empathy and Behavioral Science in ePROs to Increase Data Collection Adherence

94

Antiviral Drug Development: Overcoming Challenges to the Current Model

95

Unlocking Pre-Enrollment Data to Help Sponsors Recruit and Enroll More Patients

96

Strategies to Empower Clinical Sites, Streamline Trials and Enhance Patient Care

97

The History of Tumor Vaccines, and Why the Newest RNA Cancer Vaccines Might Work

98

What Biotech CEOs Need to Know about Developing a Commercialization Roadmap

99

Simplicity in Technology Delivery for Clinical Trials

100

Micromachines, Biologic Approaches and New Tools Pushing the Boundaries in Oral

101

Combining AI and Empirical Science to Advance Cancer Immunotherapies

102

The Personal Impact of a Clinical Trial

103

The Future of Patient-Centricity: Advancing Frameworks to Achieve Greater Impact

104

Using AI to Accelerate the Next Generation of Oncology Immunotherapies

105

Immuno-Oncology Cell Therapy Data Analytics: What and How to Measure

106

What to Expect at CRAACO: Clinical Research as a Care Option 2024, in 5 Minutes

107

How to Enhance Clinical Trial Participation in Diverse Linguistic Backgrounds

108

Patient Engagement Advocate on Collaborating Successfully with Pharma

109

What to Expect at DPHARM 2024, with DPHARM Directors

110

Astellas Head of Patient Centricity on Patient-Centric Medicine Development

111

Preferences in Decentralization and Digitalization of Pediatric Clinical Trials

112

What CMOs Need to Know about Partnering with Hospitals & Clinical Research Sites

113

How CMOs Build a Network of Consultants

114

CMO Insights and Advice on Tailoring Your Pitch to Investors

115

Transitioning from Early Stage to Registrational/Pivotal Stage Development

116

Using Sustainability to Empower Patient Engagement Goals in Medicine Development

117

Discoveries from the Clinic that Help Inform IO Cell Therapy Moving Forward

118

Maximizing Regulatory Interactions

119

The CMO as a Translational Scientist

120

Optimizing the Integration of Mobile and Patient-Facing Tech in Clinical Trials

121

Delivering Exceptional Clinical Trial Experiences for Patients

122

ctDNA Potential for Prognostic Stratification, Tumor Insights & Drug Development

123

What to Expect at the 2024 Patients as Partners EU Conference

124

Taking Lessons from Manufacturing Immunotherapies to Accelerate Development

125

Enhancing Solubility with Novel Excipient Technologies

126

Measuring the Value of DCTs and Hybrid Models

127

Navigating and Adopting Innovation in a Post- Pandemic World

128

Turning a Search for Lung Cancer Biomarkers into a Patient Empowerment Community

129

Engaging All Stakeholders for Clinical Trial Patient Engagement and Value

130

Optimizing Medicine Development for Real-World Efficacy in Patients

131

How CMOs can Support the Overarching Process of a Fundraising

132

Prioritizing Development Programs that Align with Fundraising Catalysts

133

Interacting with Different Types of Investors as a CMO

134

Developing Internal and External Communication Strategies

135

What CMOs Need to Know About Medical Affairs

136

Achieving Targeted Delivery of Gene Editing Therapies

137

The Promise and Challenges of Ultrasound-Mediated Delivery

138

The Future of Digital Technology in the Connected Device Space

139

New Approaches in CNS/PNS Delivery

140

Precision Ophthalmic Delivery

141

Delivery Challenges from the Oncology Pipeline

142

Novel Nasal Products and Formulations

143

Overcoming Barriers to Adoption of Transdermal Delivery

144

Addressing the Clinical Operations Workforce Gap

145

Evolving US Clinical Trial Infrastructure for Better Trials & Emergency Response

146

Community Organization Perspectives on Improving Clinical Trial Initiatives

147

Patients on How R&D Organizations Can Better Operationalize Trials for Patients

148

Novartis’ Approach to Making Patients Feel Valued in Clinical Research

149

How Henry Ford Health Integrated Clinical Trials into Clinical Care

150

Reimbursement Challenges with Clinical Trials

151

Democratizing Access: Enabling All Care Locations to be Research Locations

152

Strategies for Building a Successful Clinical Research Team in the Care Setting

153

How to Optimize Inventory and Sample Management for Clinical Trial Health

154

Ensuring That Sites Are Set Up for Trial Success, Using Data and Technology

155

Innovating Patient Recruitment: A Conversation with BBK Worldwide Founders

156

10th Annual Mobile Tech in Clinical Trials: What to Expect in under 10 Minutes

157

CRAACO Director's Note Podcast on What to Expect in Under 6 Minutes

158

Current Challenges in Vaccine Delivery and Distribution

159

Providing the Right Level of Value to the Patient that Creates Value

160

Enhancing the Interferon Pathway to Attack Cancer

161

Innovative CRISPR-based Editing to Create Off-the-shelf Immune Cell Therapies

162

Investment Trends in IO

163

Investment and Collaboration Strategies in Cell and Gene Therapy

164

Mechanisms of Immune Evasion Mediated by Hypoxia- Inducible Factors

165

Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Pri

166

Regeneron’s Approach to Strategic Collaborations, Licensing and Business Dev.

167

Panel: Targeted Radiotherapy and the Impact on IO

168

What’s Next on the IO Radar? Top 10 Recommendations from Dr Andrew Baum, Citi

169

KEYNOTE FIRESIDE CHAT with Dr Robert Langer and Dr Ester Caffarel-Salvador

170

Panel: Role of China in the BD Process

171

Gaining “Hard-to-Reach” Patients’ Input During the Global COVID Pandemic

172

How Janssen is Collaboratively Working with Patients and Sites to Advance DCTs

173

How Merck is Partnering with Communities to Support Clinical Research

174

Sanofi’s New Initiatives Firmly Embedding Patient Experience & Perspectives

175

Reflections on Alnylam and Conquering Delivery

176

Patient Involvement Legal Barriers to Be Aware of and Pathways to Overcome Them

177

Next Generation Immune Checkpoints: Deciphering Key Roles in the TME

178

Merck Reporting on Site Monitoring, Performance and Database Lock

179

The Role of RWD in the Development of Remdesivir

180

De-risking Combination Product Development Involving L Volume Sub Formulations

181

How Regeneron Got an FDA Approved Therapy for COVID in Record Time

182

Remote Monitoring to Improve Transitioning Home and Reducing Risk of Readmission

183

The Pfizer Pledge: Getting to 60% Remote Clinical Trials in 2022

184

Benchmarking Clinical Operations for Digital Maturity

185

Innovative Trial Designs to Reduce Patient, Site and Investigator Burden

186

Addressing the Lack of Structured, Clean Patient Data

187

Fireside Leadership Lessons: Driving Innovation to Support Patients and Sites

188

Why Rare Disease Therapeutics Need Early Market Access Planning

189

Effective Concentration for a Longer Period with Long Acting Injectables

190

Moderna on Innovating Clinical Trial Partnerships to Expand Access

191

Regeneron and Novartis on Innovating to Accommodate Growing Pipelines

192

Development of the Lipid Nanoparticles

193

Targeting TGF Beta in IO: Mechanisms, Challenges and Opportunities

194

Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies

195

Chair’s Opening Presentation with Barbara Lueckel Summary

196

A Decade After Checkpoints- What Do We Know, What Do We Need to Know and Getting

197

Achieving Diversity and Inclusion in Oncology Clinical Trials

198

How Long-Acting Implantables Are Taking Extended Drug Release to the Next Level

199

Advancements in CART for the Treatment of Glioblastoma

200

From Carer to Trailblazer: One Man’s Fight to Impact Clinical Research

201

Cell & Gene Therapy: Current Landscape, Lessons Learned and Paths Forward

202

What to Expect at the IO360° Summit in 6 Minutes

203

Solving for the Digital Divide: Building Trust with Mobile Tech for Patients

204

How Moderna Built a Digital Organization to Transform How Clinical Research Gets

205

Roche’s Industry Overview on the Drug Delivery Landscape 2022

206

Leveraging Mobile Technologies in the Development of Novel Digital Endpoints

207

How Mobile Tech is Enabling Smarter Trial Designs for Better Data and Access

208

FDA Update on Digital Health Technologies in Clinical Trials Draft Guidance

209

Taking Patient Involvement in Clinical Publications to New Heights

210

Partnering with Your Compliance Teams to Advance Meaningful Collaboration

211

What Statisticians Wish They Could Tell Their Chief Medical Officers

212

Tackling the Manufacturing Complexity of Complex to Deliver Pipelines

213

Misaligned Incentives: Physician Perspectives on the Integration of CRAACO

214

Rewriting the Way We Work Together to Integrate Clinical Care and Research

215

Volunteering for a Vaccine Trial, Tackling Racial Disparities in Healthcare

216

How Amgen is RISING Above with Clinical Trial Diversity

217

A Vision for the Integration of Clinical Research and Care

218

Addressing Barriers to Patient Community Access through Non-Profit Partnerships

219

Educating Patients and Non-Research Physicians on Navigating Clinical Research

220

Long Acting Injectables for Biologics

221

Where and How DCTs Can Truly Enable and Close the Gaps between Research and Care

222

Partnering with Health Systems to Enhance Diverse Patient Access in Trials

223

Novartis’ Approach to Patient Engagement

224

Workforce Planning & Reducing Churn to Support and Promote CRAACO

225

Guest Keynote Connecting Communities with the CEO of Etsy

226

Making Institutional Change to Offer Clinical Research Options in Health Systems

227

Microgravity to Develop Crystalline Monoclonal Antibodies for Subcutaneous

228

CMO-CEO Fireside Discussion on Working Through Challenges

229

Building Trust to Ensure Diversity, Equity, Inclusion in Clinical Research

230

Drug Delivery Pipeline and Technologies, a Year in Review

231

How Eli Lilly is Diversifying and Engaging Patients Using DCT Capabilities

232

Advice for Partnering Between Innovator Drug Delivery Companies and Big Pharma

233

Fighting to be a True Stakeholder in Clinical Care and the Impact on Diversity

234

The First 90 Days as a CMO

235

R&D Veteran on Leading a Biotech through Founding, IPO and Acquisition

236

Building up a Company Through to Commercialization and Beyond

237

Best Practices for Cross Functional Communication Strategies for the CMO

238

Nicholas Warne Drug Delivery Industry

239

Managing the Partnership Between Big and Small Pharma

240

Infusing Patient Perspectives Across All of Pfizer

241

The Changing Environment Around Accelerated Approvals and Regulatory Pathways

242

Positioning Yourself For Board Roles and What to Expect as a CMO in Biotech

243

Biotech Financing Options and Their Implications

244

Building a Work Culture that Attracts and Retains Talent in Biotech

245

Exploring Ways to Reduce Costs of Developing & Manufacturing Drug Delivery Tech

246

Taking on the CMO Role at Moderna and Looking to the Future of Biotech R&D

247

What CMOs Must Know About How Patient Engagement Supports the Entire Biotech

248

Operationalizing the Integration of Patient Insights

249

How Sites Using Their Own Technology for Research Benefits All Stakeholders

250

Adjusting Your eCOA Strategy For Patient Centricity: Expert Advice

251

Sandoz's Chief Operating Officer Discusses the New Initiative Act4Biosimilars

252

A Natural Language Collaboration That Helps Cancer Patients Navigate Treatment

253

12th Annual DPHARM in Under 10 Minutes

254

Director's Notes on What to Expect at CRAACO: Clinical Research as a Care Option

255

What to Expect at Mobile Tech in Clinical Trials 2022

256

5 Minute Overview Podcast on What to Expect at PODD: Drug Delivery

257

Key Role of Strategy and Media in Improving Clinical Trial Enrollment Diversity

258

How CMOs Can Evaluate Potential Outsourcing Partners Effectively

259

Is the End of SDTM in Sight?

260

What Adapting During COVID-19 Taught Us About Innovating Drug Development

261

A Vision for the Future of Drug Delivery: Patients Interacting Less with Disease

262

How Listening Tech Disrupts Clinical Research to Create Patient-Centric Trials

263

On-the-Ground Perspective on Putting Decentralized Strategies in Clinical Trials

264

Biotech CEO Keynote, Dr Ron Cohen, from Chief Medical Officer Summit 360° 2021

265

R&D Veteran Keynote, Dr Jo Viney, from Chief Medical Officer Summit 360° 2021

266

10th Annual Chief Medical Officer Summit 360º in a Nutshell

267

The Case for Sites Using Their Own Tech to Accelerate Research and Reduce Burden

268

5 Talks to Watch (and Why) at IO360º 2022 with Strategic Advisor Dr Dan Chen

269

8th Annual Immuno-Oncology 360° Summit: What to Expect in 7 Minutes

270

Patients as Partners EU 2022 in 5 Minutes

271

How Artificial Intelligence Is Creating Better Clinical Trials, with Saama

272

Making the Leap from IV to Subcutaneous, with Halozyme's ENHANZE® Technology

273

J&J Vision on Progress in Eyecare and Meeting the Needs of Future Patients

274

Flexible Data Collection and Best DCT Strategies: Advice from an Expert

275

Building a Successful Relationship with your Development Partner

276

9th Annual Chief Medical Officer Summit 360° Overview in 5 Minutes

277

10 Year Review on Drug Delivery

278

8th annual Mobile in Clinical Trials in 5 Minutes

279

PODD 2021 in 7 Minutes with Director, Valerie Bowling

280

Ferring on Creating a First-in-Class Microbiome-Based Therapeutic

281

DPHARM in 10 Minutes with Director Valerie Bowling

282

The Biotech Incubator Helping Entrepreneurs Launch Companies to Advance Health

283

How and When to Pursue Decentralized Clinical Trials: Conversation with Experts

284

How to Utilize Technology to Truly Increase Diversity in Clinical Trials

285

Insights from CRAACO 2020 and Looking to the Future

286

The Practical Implementation of Sensors in the Changing Drug Development World

287

Patients as Partners Europe 2021 Overview in 5 Minutes

288

Innovations & Novel Approaches in IO Imaging & Assessing Responses

289

HLA Loss and the Impact on Immunotherapy

290

Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination

291

Operational Dynamics of Implementing & Managing Basket Trials

292

Overcoming Site Regulatory Issues to Optimize Clinical Quality

293

Evolution of Regulatory Policy For Cell/Gene Therapy

294

Centralized vs Decentralized Manufacturing

295

Next Generation Bispecifics in Solid Tumors

296

Ariella Chivil's Immunotherapy Trial Pathway

297

Insitu Vaccinations vs Systemic Neo-Epitope Vaccinations

298

What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle?

299

Using Sensor Technology to Deploy Decentralized Trials and Improve Patient Care

300

Current Issues and Potential Solutions for Site Audit Readiness and Monitoring

301

5 Minute Overview of 8th Annual CMO Summit 360º

302

The Future of Clinical Research and the Innovation from the COVID-19 Pandemic

303

Connecting Care and Research for the Patient with a Decentralized Trial Model

304

Remote Monitoring for Clinical Research in the Digital Age

305

Solving for the Patient Retention Problem in Clinical Research

306

IO Combinations 360° Overview in 7 Minutes

307

Enabling Clinical Trial Continuity with Live Video Visits

308

Roche's Dr Barbara Lueckel's Opening Remarks and the 2018 Year in Review

309

How a Gene Therapy for Duchenne Muscular Dystrophy Came to Be

310

How a Covid-19 Research Study was Formed with Oracle, Javara and Wake Forest

311

IO Biomarker Discovery & Personalized Cancer Therapy Development with Personalis

312

The Impact of COVID-19 on Clinical Trials: Where are We? And Where are We Going?

313

7th Annual Mobile in Clinical Trials Overview in Under 5 Minutes

314

KPIs that Support Innovation for Patient-Engagement

315

Starbucks: Innovation for the End User Experience

316

Transparency and the Future of Patient Expectations

317

Turning Genes into Medicines: Gene Therapy for Genetic Disease

318

Formulation & Device Lifecycle Management for Biotherapeutics

319

Future Outlook for Novel Drug Delivery

320

Modality Fluid Development: Evolving Pipelines and Drug Delivery Solutions

321

MedTech Fireside Chat: The Journey of an Emerging Medical Device Company

322

Case Study: Forming and Managing a Drug Delivery Alliance

323

Supporting Business Models for Scaled Connected Health Drug Delivery Products

324

Utilizing Digital Health Data to Improve Management, Prevention & Wellness

325

Understanding Jansen's Metaphyseal Chondrodysplasia

326

The Collective Struggle to Evolve Data and Analytics Culture & Capabilities

327

Re-Thinking Clinical Development - Using Historical Data to Transform Trials

328

The Evolution of Using Real World Data to Create Trial Readiness Cohorts

329

The PD-FIDI: Developing a Digital Endpoint for Parkinson's Disease

330

Planning For and Addressing Missing Data in Mobile Clinical Trials

331

Balancing Innovation with Solid Common Sense to Deliver Innovative Medicines

332

Virtual Trials: What are We Striving for and Measurements of Success

333

Escaping Pilotville: How to Scale Mobile / Digital Deployment in Clinical Trials

334

Merck's Strategy to Mobilize Mobile Efforts and Engineer for Scale

335

What Does a Successful Digital Trial Look Like?

336

Advocating for People Managing Hermansky-Pudlak Syndrome

337

Maintaining Clinical Trial Patient Engagement in COVID with Be the Partner

338

Setting Up Therapeutic + Vaccine Programs for COVID-19: Lessons Learned

339

Understanding Spinal Muscular Atrophy: A Chief Scientific Officer's Perspective

340

Changing How We Treat Systemic Sclerosis

341

New Opportunities for Cell Therapy Combinations

342

PD1 Resistance with a Multi-Omic Approach

343

Updates on PARP Inhibition

344

Leveraging the Tumor Microenvironment for IO Therapy

345

Updates on Bintrafusp alfa/M7824 Clinical Data

346

NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies

347

Advancing Bispecifics for Combination Immunotherapy

348

How AI, Machine Learning and Big Data are Used to Inform Combinations

349

Weighing Your Options in Considering Clinical Trials from a Patient Perspective

350

Understanding the Goals of Care vs Research

351

6 Min Podcast on What to Expect at the 7th Annual Patients as Partners

352

How to Integrate Industry Sponsored Clinical Trials Into Your Health System

353

How Sanford Health Systems Increased Clinical Trial Participation to 10%

354

Keynote: Surgeon’s Perspective on Integrating Clinical Care & Clinical Research

355

How Wilmington Health is Streamlining Integration of Clinical Research & Care

356

Addressing Barriers Health Systems Face in Integrating Clinical Care & Research

357

Effectively Democratizing Access to Clinical Trials for All

358

Delivering an Innovative, Patient-Centric Delivery System

359

Ophthalmology: Exploring Other Routes of Administration

360

Transforming Cardiovascular Treatment with Pulmonary Delivery

361

MRI-Guided Focused Ultrasound and the Delivery of Therapeutics to the Brain

362

Better Strategies to Inform Patients on Clinical Research & Trial Participation

363

Chief Patient Advocate/Officer: Driving Culture Change from the Top Down

364

How Novartis Includes Patient Input into All Aspects of a Clinical Study

365

Patients as Partners in Clinical Research EU 5 Min Upcoming Conf Summary

366

Partnering with Patients on Clinical Development Protocols

367

Improving Clinical Research and Trials Through Pharma/Advocacy Partnerships

368

Engaging with Communities to Educate and Enroll Diverse Populations

369

Mapping Out the Patient Decision Journey

370

FDA Patient Engagement Synergistic Efforts

371

The Democratization of Patient Data Ownership: Returning Results

372

Cell & Gene Therapy Day Overview in 4 minutes

373

2020 Immuno-Oncology 360° Summit Overview in 10 Minutes

374

Fireside Chat with an R&D Veteran

375

Designing Clinical Trials for Gene Therapy - A Paradigm Shift

376

Case Study: Life of a Chief Medical Officer Pre and Post IPO

377

How the CMO of Sage Therapeutics Positioned a New Indication for FDA Approval

378

Addressing the Talent Gap in Biotech - Recruit and Retain

379

How to Navigate the Development Path from CMO to CEO

380

How do Patients Become Partners in the Sharing of Data to Advance Science?

381

Best Practices for Pharma - Patient Advocacy Partnerships

382

Merck's Next Phase of Patient Centricity in R&D

383

Clinical update on AMG 420, an anti-BCMA BiTE®

384

Connecting Employee-Centric Culture to Patient-Centric Culture

385

Eliciting Patient Experience Data to Understand Medicines Benefits/Disadvantages

386

Understanding the Language of Patients - The Value of Health Literacy

387

UCB and Parkinson's UK Collaboration Improve a Trial through Patient Involvement

388

Improving T Cell Therapies via Next Generation Technologies

389

Monetizing Science: Turning an Asset into Value through IPOs

390

IDO Changes the T-cell Balance in the Tumor Microenvironment

391

Insights from Deal Trends: Betting on Tumor Immunology

392

Living with Alzheimer’s from a Young Patient's Perspective

393

Organizational and Digital Restructuring to Scale Mobile Clinical Trials

394

How to Align the Promise of Technology with the Patient Voice

395

The Role of Digital Biomarkers and the Impact on Drug Delivery

396

PODD: Partnership Opportunities in Drug Delivery 2019 Overview in 4 Minutes

397

A Patient Perspective on Living with Parkinson's Disease and the GDNF Trial

398

The Future of Mobile Data in Clinical Trials: Challenges and Opportunities

399

Eli Lilly: How to Launch Multiple Mobile Devices in a Hybrid Setting

400

Pfizer’s Atopic Dermatitis Clinical Trial with Digital Wearable Technology

401

Merck’s Digital Health and Al Strategy: Progress Report

402

How Digital Biomarker Innovation is Modernizing Clinical Endpoints

403

Regenerative Medicine as a Disrupter in Clinical Trials

404

6th Annual Mobile in Clinical Trials: What to Expect in 4 Minutes

405

Estonia, The Digital Republic: Where Patients Own Their Data

406

Co-Creating the Industry's Scalable Solution for EHR

407

Bringing Blockchain to Life: Digitizing Clinical Supply Chain in Trials

408

Bayer: Virtual Assistants for Sites and Patients in Clinical Trials

409

DPharm: Disruptive Innovations in Clinical Trials 2019 Overview in 5 Minutes

410

Entrepreneur Data Scientist, Ben Liu on Solving Bottlenecks in Clinical Research

411

Stories from Bioinspiration to Innovation

412

Including Wellness in the Pharma Model - How Drug Delivery will be a Key Enabler

413

Service & Patients in Clinical Trials

414

Panel: Delivering mRNA Drugs and Vaccines – Progress and Future Outlook

415

How to Innovate like Amazon to Modernize Clinical Trials

416

Alzheimer’s Studies: Exploring Registries to Improve Enrollment & Trial Design

417

4th Annual IO Combinations 360°: What to Expect in 8 Minutes

418

CAR-T Therapy: Optimization Through Engineering T-cells or Combinations

419

Combining IO Modalities In a Cost Effective, Patient Beneficial Manner

420

IO Partnering Strategies In an Increasingly Complex Environment

421

Next Generation Biomarker and Companion Diagnostics for Predicting Response

422

Innovations in Immuno-Oncology Imaging

423

2nd Annual Drug Delivery West - 5 Minute Overview

424

Modernizing Clinical Trials with IQVIA's Dr Cynthia Verst

425

Integrating Care and Research with Dr Laura Esserman

426

Drug Delivery Global Health Challenge

427

Patient Perspectives on Drug Delivery Needs Present and Future

428

What are the Regulatory and Ethical Concerns of Integrating Care and Research?

429

How Can We Work with Medical Practices to Offer Patients Clinical Trials?

430

Why Are Clinical Trials Not Typically a Care Option?

431

How to Move Clinical Research into Communities That Would Truly Benefit

432

Lessons Learned from a Veteran Biotech and Investor MD

433

Case Study: Preparing for the Challenges of Late Stage Trials

434

Should Patients Have the Right to Try?

435

Best Practices in Communication and PR Strategy

436

Translating Patient Insight and Patient Experience Internally into Deliverables

437

Progress and Future Outlook of Cancer Immunotherapy

438

Panel: Engaging Patients By Giving Them their Data

439

Mobile Technology in Clinical Trials: Clinical Trials Transformation Initiative

440

How GSK Implemented Pivotal End-to-End Engagement Initiatives at Different Stage

441

How to Make Patient Involvement Sustainable Throughout Medicines Development

442

What Does a Truly Patient-Centered Healthcare System Look Like in 5-10 Years?

443

6th Annual Patients as Partners US: What to Expect in 8 Minutes

444

How Partnering with Medical Research Charities is Key to Medicines Development

445

Patients as Partners Europe 3rd Annual What to Expect in 5 Minutes

446

How Tesaro is Integrating the Patient in the Clinical Development Process

447

Keytruda in Combo with Chemo in NSCLC

448

Future Value Generation in Immuno-Oncology

449

Reflections of the Cancer Moonshot and Future of the Biden Cancer Initiative

450

Balancing Benefit and Toxicity from Immunotherapeutics

451

The BioCentury Report on Immuno-Oncology Industry Trends

452

5th Annual Immuno-Oncology 360˚: 12 minutes of What to Expect

453

Partnership Opportunities in Drug Delivery 2018: What to Expect 5 Min Podcast

454

Podcast: From a Zimbabwean Village Kid to a PhD Regenerative Medicine Student

455

All of Us Research Program, a Nation-wide Initiative from the NIH

456

Reimagining Clinical Trials with Entrepreneur, Dr Ben Liu, CEO, Trialspark

457

Blockchain Opportunities for Patient Data Donation and Clinical Research

458

DPharm Podcast: What to Expect at the 2018 Event in 8 Minutes

459

Mobile in Clinical Trials Podcast: 3 1/2 Minutes on What to Expect

460

What to Expect at Rational Combinations 360° 2018 - 5 Min Overview

461

How to Innovate in the Drug Delivery Space

462

Key Trends in Drug Delivery: Expert Perspective

463

How FARA and Horizon Pharma Partnered to Improve Clinical Development

464

How Takeda Used One or More of the Various Patient Engagement Frameworks

465

How Patient Research Advocates are Driving R&D: A Patient Case Study

466

Fireside Chat: Lessons Learned from a Drug Delivery Pioneer and Risk-Taker

467

Nanotechnology Keynote

468

Utilizing a Device Platform Technology across Multiple Therapeutic Categories

469

CEO Keynote Fireside Chat

470

Addressing R&D Challenges using Drug Delivery Technologies

471

Panel: Hitting the "Reset" Button on Direct-to-CNS Delivery

472

Current and Emerging Drug Delivery Needs in Oncology

473

Building Blocks of IO Clinical Trials - Part 2

474

Building Blocks of IO Clinical Trials - Part 1

475

Endpoints News Industry Report on IO Collaborations and Trends

476

CTTI Report - Mobile Clinical Trials Program: Recommendations on Novel Endpoints

477

How a Mobile App Can Offer Unique Value in Assessing Patient Reported Outcomes

478

Lessons Learned from the Journey of a CMO Leader, Michael Rosenblatt, MD

479

Developing a Pathway for Compassionate Use Cases

480

2018 Chief Medical Officer Summit Podcast Overview in a Nutshell

481

Clinical Research as a Care Option, 2nd annual - 3 min Podcast Overview

482

What to Expect at Clinical Trial Collaborations 2018 – 5 min Podcast

483

Mobile in Clinical Trials Europe New for 2018 - 4 min Podcast Overview

484

Patients, a Seat at the Table in Clinical Trials with Pfizer’s Dr Roz Schneider

485

Reducing the Burden of Type 1 Diabetes with Patient Dana Lewis:DPharm Podcast #5

486

5th Annual Patients as Partners What to Expect Overview Podcast in 7 Minutes

487

Wireless Remote Monitoring – DPharm Podcast Series #2

488

Immuno-Oncology Clinical Trial Operations 4 Min Summary of What to Expect

489

Patients as Partners EU Overview in 3 Minutes

490

Roche's Dr Barbara Lueckel Reviews the 2016 Drug Delivery Industry

491

From the Olympics to Clinical Research

492

What to Expect at Immuno-Oncology 360° 2018

493

Why Pharma R&D has to Start Thinking Like a Service Industry and How?

494

The Gap Between Clinical Care, Patient Involvement & What Patients Want

495

Digital Solutions Impacting the Economic Efficacy of Clinical Trials

496

Partnering with Patient Organizations for Advancing Cures

497

Challenges and Opportunities in Pursuing a New Therapeutic Modality

498

Partnering with Patients in the Development and Lifecycle of Medicines

499

Trends and Collaborations in the IO Space

500

Unlocking the Power of Patient Engagement within Clinical and Commercial

501

Patients Influencing Policy in the EU

502

Immuno-Oncology 360°: Business Models for Complex Science by Dr Axel Hoos of GSK

503

Increasingly Critical Role of Predictive Biomarkers in Cancer Immunotherapy

504

Important Business Aspects of Immuno-Oncology: Issues and Controversies

505

Innovative Ways of Patient Involvement in Medicines Development

506

Addressing Clinical Challenges in Immuno-Oncology

507

Sequencing of Combination Agents in Immuno-Oncology with Dr Charles Drake

508

Next Generation of Combination Immunotherapy with Dr Patrick Hwu of MD Anderson

509

Patients as Partners Europe 7 Minute Overview on What to Expect?

510

5 Minute Overview of DPharm (Disrupting Clinical Trials) Europe: What to Expect?

511

Immuno-Oncology 360 Conference in 5 Minutes: What to Expect?

512

DPharm Team Discuss 2016 Highlights

513

Pfizer's Blue Sky Approach to Help Transform Clinical Research

514

Communicating the Good, Bad & Ugly for CMOs and R&D Leaders in Biotech

515

Clinical Trial Opportunities in Puerto Rico

516

Alternative Model to Transform a Funding Gap in Rare Disease Clinical Research

517

A New Economic Solution to Drive Cures to Patients

518

Partnering with Patients in the Development & Lifecycle of Medicines

519

Immuno-Oncology Drug Development: Challenges & Next Steps

520

Making Clinical Trials a Care Option for Patients: Piloting an Infrastructure

521

Safety Elements of Cancer Immunotherapies: Immune Related Adverse Events

522

How the Availability of Capital Impacts the Role of the CMO

523

How Investors Assess R&D Biotech Management

524

The Journey of a Physician CEO with David Schenkein, MD, CEO, Agios

525

Clinical Air Episode #14 Consumer Electronics in Clinical Research

526

Immuno-Oncology: Exploring the Challenges & Potential

527

Design Thinking for Clinical Trials

528

Clinical Air Episode #13 Transcelerate & Industry Engagement

529

Risk Based Monitoring: New Thinking on Clinical Oversight

530

Clinical Air Episode # 12: Digital Startups & Applications for Clinical Research

531

Clinical Air Episode #11: How can Digital Complement and Disrupt Clinical Trials

532

Clinical Air Episode # 10 Patients as Partners in Clinical Trials

533

Clinical Air Episode # 9 Investing in the Future of Clinical Research

534

Clinical Air Episode # 8: Investigators as Partners in Clinical Research

535

Clinical Air Episode # 7: Engaging Patients by Sharing Electronic Clinical Data

536

Clinical Air #6 Clinical Trial Visits of the Future

537

Barriers and Limitations in Engaging Patients in Clinical Trials

538

Clinical Air Episode #5 Applications for Mobile/Sensors in Clinical Research

539

Clinical Air Episode #4 Clinical Innovation Continuum

540

Clinical Air Episode #3 Dpharm & Beyond

541

Clinical Air Episode #2:To Serve Patients in Clinical Trials

542

Managing the Role of Chief Medical Officer in a Biotech

543

Navigating the Complexities of Global Clinical Trials

544

Clinical Air Episode #1: Clinical Trial Calling